Microglial Adenosine Receptors: From Preconditioning to Modulating the M1/M2 Balance in Activated Cells

dc.contributor.authorFranco Fernández, Rafael
dc.contributor.authorLillo, Alejandro
dc.contributor.authorRivas‐Santisteban, Rafael
dc.contributor.authorReyes Resina, Irene
dc.contributor.authorNavarro Brugal, Gemma
dc.date.accessioned2022-03-30T12:28:42Z
dc.date.available2022-03-30T12:28:42Z
dc.date.issued2021-05-01
dc.date.updated2022-03-30T12:28:42Z
dc.description.abstractNeuronal survival depends on the glia, that is, on the astroglial and microglial support. Neurons die and microglia are activated not only in neurodegenerative diseases but also in physiological aging. Activated microglia, once considered harmful, express two main phenotypes: the pro-inflammatory or M1, and the neuroprotective or M2. When neuroinflammation, i.e., microglial activation occurs, it is important to achieve a good M1/M2 balance, i.e., at some point M1 microglia must be skewed into M2 cells to impede chronic inflammation and to afford neuronal survival. G protein-coupled receptors in general and adenosine receptors in particular are potential targets for increasing the number of M2 cells. This article describes the mechanisms underlying microglial activation and analyzes whether these cells exposed to a first damaging event may be ready to be preconditioned to better react to exposure to more damaging events. Adenosine receptors are relevant due to their participation in preconditioning. They can also be overexpressed in activated microglial cells. The potential of adenosine receptors and complexes formed by adenosine receptors and cannabinoids as therapeutic targets to provide microglia-mediated neuroprotection is here discussed. Keywords: neurodegeneration; aging; Parkinson's disease; Alzheimer's disease; neuroprotection; neuronal survival; cannabinoids; receptor heteromers
dc.format.extent18 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec714175
dc.identifier.issn2073-4409
dc.identifier.urihttps://hdl.handle.net/2445/184526
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/cells10051124
dc.relation.ispartofCells, 2021, vol. 10, num. 5, p. 1-18
dc.relation.urihttps://doi.org/10.3390/cells10051124
dc.rightscc-by (c) Franco Fernández, Rafael et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Bioquímica i Biomedicina Molecular)
dc.subject.classificationMalaltia de Parkinson
dc.subject.classificationMalaltia d'Alzheimer
dc.subject.classificationMalalties neurodegeneratives
dc.subject.otherParkinson's disease
dc.subject.otherAlzheimer's disease
dc.subject.otherNeurodegenerative Diseases
dc.titleMicroglial Adenosine Receptors: From Preconditioning to Modulating the M1/M2 Balance in Activated Cells
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
714175.pdf
Mida:
1.22 MB
Format:
Adobe Portable Document Format